HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kazuhiro Ito Nobuo Kitamura Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, K. Articles by Kitamura, N. Search for Related Content PubMed PubMed Citation Articles by Ito, K. Articles by Kitamura, N. Related Collections Lung - transplantation

Eur J Cardiothorac Surg 2004;25:530-536
© 2004 Elsevier Science NL

Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor- ligand, on lung ischemia-reperfusion injury in rats

^a Department of Cardiovascular and Thoracic Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
^b Department of Internal Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Received 18 June 2003; received in revised form 29 November 2003; accepted 14 December 2003.

^* Corresponding author. Tel.: +81-75-251-5752; fax: +81-75-257-5910
e-mail: kazuitoh{at}koto.kpu-m.ac.jp

Objectives: Lung injury induced by ischemia-reperfusion is the main cause of early graft failure after lung transplantation, which may result from oxygen-free radicals, inflammatory cytokine production, and polymorphonuclear leukocyte accumulation into the interstitium, resulting in severe lung edema. Peroxisome proliferator-activated receptor- (PPAR-) belongs to the nuclear receptor superfamily and has an anti-inflammatory effect by preventing the activation of transcription factors such as nuclear factor-B (NF-B). NF-B regulates the expression of many genes of early response products in the development of acute inflammation. We examined the effects of pioglitazone, a synthetic ligand of PPAR-, against lung ischemia-reperfusion injury in rats. Methods: The left lungs of male Wistar rats were rendered ischemic for 90 min and then reperfused for 2 h. Treated animals received pioglitazone (10 mg/kg) 2 h before induction of ischemia. Lung injury was quantified in terms of lung microvascular permeability (Evans blue dye extravasation), tissue lipid peroxidation (thiobarbituric acid reactive substances), and tissue polymorphonuclear leukocyte accumulation (myeloperoxidase activity). The tissue concentrations of tumor necrosis factor- (TNF-) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) were also measured. Statistical analyses were performed by one-way analysis of variance, followed by Sheffe's multiple comparison test. Results: The lung vascular permeability in pioglitazone-treated animals was reduced by 55% of the increase of Evans blue dye extravasation relative to control animals (P=0.003). The protective effects of pioglitazone treatment were correlated with the reduction by 79% of the increase of thiobarbituric acid reactive substances (P=0.045) and the reduction by 58% of myeloperoxidase activity increase (P<0.001). The production of TNF- was reduced by 63% of the increase (P<0.001) and the reduction of CINC-1 was 45% (P<0.001). Pioglitazone did not affect the lung in the sham animals. Conclusions: Pioglitazone treatment before ischemia attenuated lung ischemia-reperfusion injury in rats. The mechanism of these protective effects involves inhibition of the production of proinflammatory cytokines, polymorphonuclear leukocyte accumulation, and tissue lipid peroxidation, resulting in reduced lung edema.

Key Words: Ischemia-reperfusion injury • Lung • Pioglitazone • Peroxisome proliferator-activated receptor-

This article has been cited by other articles:

				D G Downey, S C Bell, and J S Elborn Neutrophils in cystic fibrosis Thorax, January 1, 2009; 64(1): 81 - 88. [Abstract] [Full Text] [PDF]

				R. C. Reddy, V. R. Narala, V. G. Keshamouni, J. E. Milam, M. W. Newstead, and T. J. Standiford Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma} Blood, November 15, 2008; 112(10): 4250 - 4258. [Abstract] [Full Text] [PDF]

				H. Wu, B. Ren, J. Zhu, G. Dong, B. Xu, C. Wang, X. Zheng, and H. Jing Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 902 - 907. [Abstract] [Full Text] [PDF]

				H. Kono, H. Fujii, Y. Hirai, M. Tsuchiya, H. Amemiya, M. Asakawa, A. Maki, M. Matsuda, and M. Yamamoto The Kupffer cell protects against acute lung injury in a rat peritonitis model: role of IL-10 J. Leukoc. Biol., April 1, 2006; 79(4): 809 - 817. [Abstract] [Full Text] [PDF]

				T. J. Standiford, V. G. Keshamouni, and R. C. Reddy Peroxisome Proliferator-activated Receptor-{gamma} as a Regulator of Lung Inflammation and Repair Proceedings of the ATS, October 1, 2005; 2(3): 226 - 231. [Abstract] [Full Text] [PDF]

				D. Suri and R. E. Weiss Effect of Pioglitazone on Adrenocorticotropic Hormone and Cortisol Secretion in Cushing's Disease J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1340 - 1346. [Abstract] [Full Text] [PDF]

				M. Abdelrahman, A. Sivarajah, and C. Thiemermann Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock Cardiovasc Res, March 1, 2005; 65(4): 772 - 781. [Abstract] [Full Text] [PDF]